This practice has not been clinically studied or approved, and carries substantial risks of infection and accidental overdose
Jin J, Liao Z, Zhang Z, Ajani J, Swisher S , Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R
This approach is limited by the categorical nature of fibrosis staging, which may not fully reflect changes within stages or accurately predict clinical outcomes4, and improvements in fibrosis do not always correlate with immediate clinical outcomes, complicating the interpretation of trial results4
If a clinician is tracking anything objective, the more relevant markers are things like liver enzymes or metabolic labs over weeks to months, not day-to-day scale changes
July 14 (UPI) -- Folks using GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, a new study says